Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT00730301
Other study ID # EUROPT 07-074-0507
Secondary ID
Status Unknown status
Phase Phase 4
First received August 5, 2008
Last updated August 5, 2008
Start date July 2007

Study information

Verified date August 2008
Source LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
Contact Arschang Valipour, MD
Phone +43-1-91060-41833
Email arschang.valipour@wienkav.at
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of a new treatment algorithm for bronchoscopic lung volume reduction (BLVR) in patients with emphysema based on the information of emphysema heterogeneity, destruction score, and fissure analysis.


Description:

Emphysema is a progressive pulmonary disease characterized by abnormal and permanent enlargement of air spaces distal to terminal bronchioles accompanied by the destruction of pulmonary parenchyma. Treatment includes inhaled bronchodilator therapy, rehabilitation and/or oxygen treatment. In addition to the above, patients with severe emphysema may benefit from surgical lung volume reduction and/or lung transplantation. The rationale for lung volume reduction surgery is that reducing lung size would restore elastic recoil of the lung and improve chest wall and diaphragm mechanics. It has previously been shown that particularly patients with heterogeneous emphysema seem to benefit most from surgical lung volume reduction.

Bronchoscopic lung volume reduction (BLVR) has recently been introduced as a less invasive potential alternative to surgical lung volume reduction. BLVR attempts to achieve the effects of surgery, by placing bronchial prostheses using a fibreoptic bronchoscope to selectively occlude the airways supplying the most affected hyperinflated regions of the emphysematous lung, while permitting exhaled gas to escape. This attempts to achieve segmental or lobar volume reduction, simulating the effects of surgical LVR. Recent trials of BLVR using endobronchial one-way valves demonstrated significant improvements in lung function parameters, exercise capacity and quality of life in patients with end-stage emphysema. The treatment algorithm for valve implantations to achieve BLVR, however, varied considerably in these reports as well as clinical and functional response rates. Subset analysis of these studies revealed that particularly, but not exclusively, patients with radiological signs of lung volume reduction treated unilaterally showed significant clinical improvements, whereas most patients without signs of lung volume reduction did not experience these benefits. The present study investigates the response to BLVR based on a new treatment algorithm including lung function criteria and computed tomography of the thorax.


Recruitment information / eligibility

Status Unknown status
Enrollment 20
Est. completion date
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- Patient diagnosed by HRCT Core Lab with eligible heterogeneous disease distribution and at least one complete oblique fissure.

- Age from 40 to 75 years

- BMI < 32 kg/m2

- FEV1 < 40% of predicted value, FEV1/FVC < 70%

- TLC > 120% predicted, RV > 150% predicted.

- Stable with < 20 mg prednisone (or equivalent) qd

- PaCO2 < 50mm Hg

- PaO2 > 45 mm Hg on room air

- 6-min walk of > 50m (without rehabilitation) or > 100m (with rehabilitation)

- Nonsmoking for 4 months prior to initial interview and throughout screening

- The patient agrees to all protocol required follow-up intervals.

- The patient has no child bearing potential

- The patient is willing and able to complete protocol required baseline assessments and procedures

Exclusion Criteria:

- Prior endobronchial treatment for emphysema

- Pleural or interstitial disease that precludes surgery.

- Prior lung transplant, LVRS, median sternotomy, bullectomy or lobectomy.

- Clinically significant bronchiectasis

- Pulmonary nodule requiring surgery

- History of recurrent respiratory infections (> 3 hospitalization in the last year)

- Clinically significant (> 4 Tablespoons per day) sputum production

- Fever, elevated white cell count, or other evidence of active infection

- Dysrhythmia that might pose a risk during exercise or training

- Congestive heart failure within 6 mo and LVEF < 45%

- Evidence or history of Cor Pulmonale

- Resting bradycardia (< 50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT

- History of exercise-related syncope

- MI within 6 mo and LVEF < 45%

- Evidence of systemic disease or neoplasia expected to compromise survival during 5-yr period

- Any disease or condition that interferes with completion of initial or follow-up assessments

- Patient is currently enrolled in another clinical trial

- Patient is unable to complete 3 minutes of unloaded peddling on cycle ergometer

- Alpha-1-Antitrypsin Deficiency

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bronchoscopic Lung Volume Reduction (BLVR)
Procedure under general anesthesia.

Locations

Country Name City State
Austria Otto Wagner Hospital Vienna
Belgium University Antwerp Antwerp
Belgium University Brussels Brussels

Sponsors (1)

Lead Sponsor Collaborator
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology

Countries where clinical trial is conducted

Austria,  Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean % change in lung function (FEV1) 90 days post index bronchoscopic lung volume reduction
Secondary Mean % change in target lobe Residual Volume and Total Lung Capacity. Mean absolute change in dyspnea (mMRC-Score), Quality of life using St. George's Respiratory Questionnaire and SF-36. 90 days post-index bronchoscopic lung volume reduction
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy